MiNK Therapeutics
INKT | NASDAQ
$9.35
+$0.01 (+0.11%)
At close: Nov 16, 2026, 4:00 PM ET
$9.26
-$0.09 (-0.96%)
After-hours:
Nov 16, 2026, 7:30 PM ET
+0.11%
(1D)No price chart data available for 1D timeframe.
Rating
38.2
+3.0 ptsFundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #576/1021 (Top 56%)
Key Statistics
Market Data
Market Cap $48M
1D Range
9.08 9.76
52W Range
8.56 14.21
Valuation (TTM)
PE -4.17
PB -2.95
EV/EBITDA -3.48
Valuation (NTM)
Forward PE N/A
Forward PEG 0.17
Price Target $35.00
Cash Flow
FCF Yield -10610.7%
SBC Adj. FCF Yield -13499.5%
SBC Impact -27.2%
Margins
Gross Margin 26.6%
Operating Margin -6006.3%
FCF Margin -2546554.9%
Growth (CAGR)
Revenue 3Y | 5Y 150.0% |
100.0%
Dil EPS 3Y | 5Y 26.7% |
28.9%
FCF 3Y | 5Y -118.2% |
-88.5%
Returns
ROA -133.8%
ROE 107.7%
ROIC -17712.6%
Financial Health
Net Cash
$7.47M
Current Ratio 0.97
Interest Coverage -12,012.50
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natur...
Sector Healthcare
Industry Biotechnology
Employees 15
IPO Date Oct 15, 2021
Website minktherapeutics.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 11, 2026
EPS
-$0.5
Beat +24.24%
YoY:
+23.08% REV
$200K
Beat +166.67%
Next Earnings
Mar 23, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
2
Consensus
Buy
Price Target
$35.00
Upside
+274.33%
Buy (2)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove INKT